IP Library Granted Patent US 10,351,572
Granted Patent B2
US 10,351,572 · App. 16/271,376 · Granted Jul 16, 2019

Aryl hydrocarbon receptor antagonists and uses thereof

Inventor: Arthur Glenn Romero (Chesterfield, MO)
Assignee: Magenta Therapeutics Inc.
C07D487/04A61K35/28C07D471/04C07D519/00C12N5/0647A61K2035/124Y02A50/401Y02A50/414
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,351,572
App. No.
16/271,376
Granted
Jul 16, 2019
Kind
B2
Abstract

The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.

Claims (37)

1. A compound represented by formula (II-f)

wherein A is an optionally substituted ring system selected from the group consisting of phenol-4-yl and 1H-indol-3-yl;

q is an integer from 0 to 4;

each Z is independently a substituent selected from the group consisting of C 1-4 alkyl, halo, halo-substituted-C1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 1-4 alkoxy, cyano, amino, C(O)R 11a , —S(O) 0-2 R 11a , —C(O)OR 11a , and —C(O)NR 11a R 11b , wherein R 11a and R 11b are each independently selected from the group consisting of hydrogen and C1-4 alkyl; and

R 5 is selected from the group consisting of isopropyl, methyl, ethyl, prop-1-en-2-yl, isobutyl, cyclohexyl, sec-butyl, (S)-sec-butyl, (R)-sec-butyl, 1-hydroxypropan-2-yl, (S)-1-hydroxypropan-2-yl, (R)-1-hydroxypropan-2-yl, and nonan-2-yl, or R 5 is selected from the group consisting of (i), (ii), (iii), (iv), and (v)

wherein n is an integer from 1 to 6, m is an integer from 0 to 6, p is an integer from 0 to 5 and each R is independently selected from the group consisting of cyano, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 1-4 alkoxy, halo, halo-substituted-C 1-4 alkyl, halo-substituted-C 1-4 alkoxy, amino, —C(O)R 12a , —S(O) 0-2 R 12a , —C(O)OR 12a , and —C(O)NR 12a R 12b , and wherein R 12a and R 12b are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;

or a salt thereof.

2. The compound of claim 1 , wherein A is 1H-indol-3-yl.

3. The compound of claim 1 , wherein each Z is independently selected from the group consisting of ethoxycarbonyl, methoxy, cyano, methyl, methylsulfonyl, fluoro, chloro, trifluoromethyl, ethylnyl, and cyclopropyl.

4. The compound of claim 1 , wherein q is 1.

5. The compound of claim 1 , wherein Z is methyl.

6. The compound of claim 1 , wherein Z is cyano.

7. The compound of claim 1 , wherein Z is fluoro.

8. The compound of claim 1 , wherein R 5 is selected from the group consisting of isopropyl, methyl, ethyl, isobutyl, cyclohexyl, hydroxypropan-2-yl and sec-butyl.

9. The compound of claim 1 , wherein R 5 is sec-butyl.

10. The compound of claim 1 , wherein R 5 is (ii).

11. The compound of claim 10 , wherein R 5 is (ii), n is an integer from 1 to 3, and m is an integer from 0 to 2.

12. The compound of claim 1 , wherein R 5 is hydroxypropan-2-yl.

13. The compound of claim 1 , wherein R 5 is 3-ethoxy-1-methylpropyl.

14. The compound of claim 1 , wherein R 5 is 1-methoxy-3-butyl.

15. The compound of claim 1 , wherein said compound is represented by formula (II-g)

16. The compound of claim 15 , wherein A is 1H-indol-3-yl.

17. The compound of claim 15 , wherein Z is methyl.

18. The compound of claim 15 , wherein Z is cyano.

19. The compound of claim 15 , wherein Z is fluoro.

20. The compound of claim 15 , wherein R 5 is sec-butyl.

21. The compound of claim 15 , wherein R 5 is (ii).

22. The compound of claim 21 , wherein R 5 is (ii), n is an integer from 1 to 3, and m is an integer from 0 to 2.

23. The compound of claim 15 , wherein R 5 is hydroxypropan-2-yl.

24. The compound of claim 15 , wherein R 5 is 3-ethoxy-1-methylpropyl.

25. The compound of claim 15 , wherein R 5 is 1-methoxy-3-butyl.

26. The compound of claim 1 , wherein said compound is selected from the group consisting of

and salts thereof.

27. The compound of claim 1 , wherein said compound is selected from the group consisting of

and salts thereof.

28. The compound of claim 1 , wherein said compound is selected from the group consisting of

and salts thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2023
From: MAGENTA THERAPEUTICS, INC.
To: EDIGENE BIOTECHNOLOGY, INC.
Reel/Frame 064224/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2019
From: GONCALVES, KEVIN A.
To: MAGENTA THERAPEUTICS INC.
Reel/Frame 048291/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2019
From: ROMERO, ARTHUR GLENN
To: PHARMA-VATION CONSULTING, LLC
Reel/Frame 048291/0924 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2019
From: PHARMA-VATION CONSULTING, LLC
To: MAGENTA THERAPEUTICS INC.
Reel/Frame 048291/0933 →
Continuity (5)
Continuation 15951585 · Apr 12, 2018
Provisional Application 62625896 · Feb 2, 2018
Provisional Application 62613382 · Jan 3, 2018
Provisional Application 62484692 · Apr 12, 2017
Related Publication 20190177330A1 · Jun 13, 2019